Curated News
By: NewsRamp Editorial Staff
August 07, 2026

Quantum BioPharma: Dual Push in MS and Alcohol Metabolism

Discuss on LinkedIn Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Quantum BioPharma's dual approach in MS and alcohol detox targets unmet markets, offering investors a diversified pipeline with potential FDA approvals.
  • Quantum BioPharma's Lucid-MS targets PAD2 to prevent myelin degradation, with an IND filed for Phase 2 trials and imaging collaboration with Mass General.
  • Quantum BioPharma's therapies aim to restore myelin in MS patients and reduce alcohol's harmful effects, improving quality of life for many.
  • Quantum BioPharma's unbuzzd supplement, from a clinical trial, could reduce hangovers, while Lucid-MS might repair nerve damage in MS.

Impact - Why it Matters

This news matters because it highlights Quantum BioPharma's innovative approach to two significant health issues: multiple sclerosis and alcohol misuse. Lucid-MS's mechanism targeting PAD2 could offer a new treatment avenue for MS patients, potentially slowing or reversing disease progression. Meanwhile, unbuzzd addresses the widespread problem of hangovers and acute intoxication, with potential implications for public health and safety. For investors, the company's progress in clinical trials and commercialization could influence the biotech sector and offer opportunities for growth.

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing a dual-pronged strategy to tackle neurological and metabolic health challenges. The company is developing Lucid-MS, an investigational therapy for multiple sclerosis (MS) that targets the enzyme PAD2, which is linked to myelin degradation. Unlike traditional MS treatments that primarily modulate the immune system, Lucid-MS aims to protect and potentially restore the myelin sheath. Quantum BioPharma has submitted an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 trial and is collaborating with Massachusetts General Hospital on imaging to support the development.

In parallel, Quantum BioPharma has introduced unbuzzd, a proprietary dietary supplement designed to support alcohol metabolism and reduce acute intoxication and hangover effects. The company cites results from a randomized, placebo-controlled clinical trial. Quantum BioPharma spun out the OTC version of unbuzzd to Unbuzzd Wellness Inc. (UWI), retaining a 19.84% ownership stake and entitlement to royalty payments: 7% of sales until $250 million is reached, then 3% in perpetuity. The company retains full rights to develop pharmaceutical-grade formulations.

Quantum BioPharma is focused on building a portfolio of innovative assets for neurodegenerative, metabolic, and alcohol misuse disorders. The company's lead compound, Lucid-MS, is a patented new chemical entity that has shown promise in preclinical models for preventing and reversing myelin degradation. Investors can stay updated with the latest news at https://ibn.fm/QNTM. The full article is available at https://ibn.fm/Rl89U.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma: Dual Push in MS and Alcohol Metabolism

blockchain registration record for this content.